Following the discontinuation of its own geographic atrophy drug, lampalizumab, Roche is jumping back on to the bandwagon with a collaboration with Ionis Pharmaceuticals to develop IONIS-FB-LRx for the treatment of complement-mediated diseases, including age-related macular degeneration (AMD). The US$759 M deal comes a little over a year after GlaxoSmithKline walked away from the drug following a reassessment of its pipeline and some months after Roche’s forecasted-blockbuster candidate, lampalizumab, was discontinued following the failure of two Phase III studies.